Sven de Vos

机构：APLA Health, University of California, Los Angeles, Ronald Reagan UCLA Medical Center, Los Angeles Medical Center · ORCID：0000-0002-6715-4851

发表论文 365 篇 · 总被引 17035 次 · h-index 53

代表论文

• Allogeneic Chimeric Antigen Receptor T-Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma: Phase I Experience From the ALPHA2/ALPHA Clinical Studies (2025 · Journal of Clinical Oncology · 被引 40)
• Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 study (2025 · Blood · 被引 21)
• Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (2025 · Journal of Clinical Oncology · 被引 15)
• 5-Year Follow-up Analysis from ZUMA-5: A Phase 2 Trial of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (2024 · Blood · 被引 15)
• Fixed-duration epcoritamab plus R2 drives favorable outcomes in relapsed or refractory follicular lymphoma (2025 · Blood · 被引 10)
• Fixed-duration epcoritamab + R-CHOP in patients with newly diagnosed DLBCL and high IPI scores (3–5) led to sustained remissions and disease-free survival beyond 3 years: Results from the EPCORE NHL-2 trial (2025 · Blood · 被引 4)